Ernesto Tovar-Sugrañes

Ernesto Tovar-Sugrañes

Auto-generated profile, based on publicly available information

Ernesto Tovar-Sugrañes

Reumatología, Hospital General Universitario de Alicante, Alicante, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MLMaría-Del-Carmen López-González
María-Del-Carmen López-González
MPMaria Luisa Peral-Garrido
Maria Luisa Peral-Garrido
ICIrene Calabuig
Irene Calabuig
ETErnesto Tovar-Sugrañes
Ernesto Tovar-Sugrañes
VJVega Jovani
Vega Jovani
Mariano AndrésMariano Andrés
Mariano Andrés

1 July 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
VJVega Jovaní
Vega Jovaní
ICIrene Calabuig
Irene Calabuig
MPMaria Luisa Peral-Garrido
Maria Luisa Peral-Garrido
ETErnesto Tovar-Sugrañes
Ernesto Tovar-Sugrañes
MLMaría-Del-Carmen López-González
María-Del-Carmen López-González
Mariano AndrésMariano Andrés
Mariano Andrés

7 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
José E. RodríguezJosé E. Rodríguez
José E. Rodríguez
EGE. Grau García
E. Grau García
CBCarmen Barcena
Carmen Barcena
AQA. V. Huaylla Quispe
A. V. Huaylla Quispe
ANA. M. Torrat Noves
A. M. Torrat Noves
JIJ. A. Román Ivorra
J. A. Román Ivorra
Background Glucocorticoids are widely used for the treatment of various rheumatic diseases and are one of the major risk factors for bone fragility associated fractures. However, beyond randomized clinical trials, there is little evidence in actual clinical practice. Objectives Our aim is to evaluate the appearance of osteoporosis and fractures in patients undergoing corticosteroid therapy. Methods We performed an observational retrospective descriptive study with Vasculitis (several subtypes) or Polymyalgia Rheumatica (PMR) patients diagnosed, who had received corticosteroid regimens with doses of at least 5 mg/day of prednisone (or equivalent) for a period of not less than 3 months, and in which the appearance of fractures was monitored for the next 2 years. Results We included 234 patients (62.4% females) with a mean age at the onset of corticosteroids of 75.8 years and mean duration corticosteroid regimens of 58 months. The most represented disease was PMR, with 183 patients (78.2%), followed by Large Vessel Vasculitis (12.4%), ANCA positive Small Vessel Vasculitis (4.3%), ANCA negative Small Vessel Vasculitis (3.4%), with a lower proportion of Medium Vessel vasculitis and other diseases such as Relapsing Polychondritis. Furthermore, 29 patients (12.39%) had previous fragility fractures, while 32 patients (13.68%) suffered one or more fractures after the start of corticosteroid therapy, being hip its most frequent location (4.7%), followed by vertebrae (3.8%). Likewise, the mean duration of corticosteroid treatment until the onset of new fractures was 4.5 months. Even without reaching statistical significance, we observed a greater age (80.5 years), a higher presence of the female gender (81.25%) and a previous fracture (18.75%) in patients with new fractures. In addition, 32.91% of patients had densitometric osteoporosis at the beginning of corticosteroid therapy. Comparison between different therapeutic options We observed an association between fractures and zoledronate treatment (P=0.012), and a tendency for ibandronate (P=0.07). The discreet entity of these differences could be explained by the statistical effect produced by the small number of new fractures, taking into account, moreover, the fact that in our Rheumatology Department we systematically carry out a fracture risk assessment to decide whether and when to start the treatment, and also prescribing more powerful therapeutic options to patients at higher risk of fracture. Finally, we did not observe significant differences in fracture-free time among the most frequent therapeutic options. Conclusion We observed a tendency to have a higher frequency of fractures in patients with previous fractures, older age and female gender. Less quantitative prevention of fractures was observed in patients with zoledronate and ibandronate, with no clear differences in fracture-free time. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests None Declared.